[1]王 瑾,吴惠琴,陈晓冬,等.羟苯磺酸钙联合复方樟柳碱治疗非增殖性糖尿病性视网膜病变临床研究*[J].陕西医学杂志,2020,49(4):489-493.
　WANG Jin,WU Huiqin,CHEN Xiaodong,et al.Clinical effect of calcium dobesilate combined with compound anisodine in the treatment of nonproliferative diabetic retinopathy[J].,2020,49(4):489-493.
点击复制

羟苯磺酸钙联合复方樟柳碱治疗非增殖性糖尿病性视网膜病变临床研究*
分享到：

《陕西医学杂志》[ISSN:1000-7377/CN:61-1281/TN]

卷:
49
期数:
2020年4期
页码:
489-493
栏目:
药物与临床
出版日期:
2020-04-05

文章信息/Info

Title:
Clinical effect of calcium dobesilate combined with compound anisodine in the treatment of nonproliferative diabetic retinopathy
文章编号:
DOI:10.3969/j.issn.10007377.2020.04.026
作者:
王 瑾; 吴惠琴; 陈晓冬; 张学辉△
西安市第一医院眼科(西安市眼科医院,陕西省眼科研究所)(西安710002)
Author(s):
WANG Jin; WU Huiqin; CHEN Xiaodong; et al.
Department of Ophthalmology,Xi'an No.1 Hospital(Xi'an 710002)
关键词:
非增殖性糖尿病性视网膜病变;  羟苯磺酸钙;  复方樟柳碱;  血管内皮生长因子;  内皮素-1
Keywords:
Nonproliferative diabetic retinopathy;  Calcium dobesilate;  Compound anisodine;  Vascular endothelial growth factor;  Endothelin-1
分类号:
R774
文献标志码:
A
摘要:
目的:探讨羟苯磺酸钙(CaD)联合复方樟柳碱治疗非增殖性糖尿病性视网膜病变(NPDR)的临床效果。方法:收集120例单眼NPDR患者,采用平行随机对照法分为对照组和观察组,各60例60眼。两组均给予控制血糖、饮食运动疗法等常规治疗处理,对照组患者常规口服羟苯磺酸钙胶囊治疗,观察组在对照组的基础上加用复方樟柳碱双颞侧皮下注射,两组均持续治疗3个月。对比两组治疗前后视力、眼底病变以及相关血清细胞因子血管内皮生长因子(VEGF)和内皮素-1(ET-1)的变化,综合评估并比较两组的治疗效果。结果:观察组总有效率高于对照组(P<0.05),视力较对照组有所提升,眼底微动脉瘤个数和出血、渗出面积较对照组减少,两组比较差异均具有统计学意义(P<0.05); 经治疗后观察组血清VEGF、ET-1水平较对照组显著降低,两组比较差异均具有统计学意义(P<0.05)。结论:CaD联合复方樟柳碱治疗NPDR可有效改善患者视力,减轻眼底病变,降低VEGF和ET-1水平,临床治疗效果显著。
Abstract:
Objective:To investigate the clinical effect of calcium dobesilate(CaD)combined with compound anisodine in the treatment of nonproliferative diabetic retinopathy(NPDR). Methods:120 cases of monocular NPDR patients were collected and divided into the control group and the observation group by parallel randomized control method,with 60 cases and 60 eyes in each group. Both groups were treated with routine treatments such as blood glucose control,diet and exercise therapy,etc. Patients in the control group were treated with routine CaD capsules orally,and those in the observation group were injected with compound anisodine on the basis of the control group. Both groups received continuous treatment for 3 months. The changes of visual acuity,fundus lesions and related serum cytokines vascular endothelial growth factor(VEGF)and endothelin-1(ET-1)in the two groups were observed before and after treatment,and the therapeutic effects of the two groups were comprehensively evaluated and compared. Results:The total effective rate of treatment in the observation group was higher than that in the control group(P<0.05). Visual acuity of the observation group was improved compared with the control group,and the number of retinal microaneurysm,bleeding and exudation area were decreased after treatment in the observation group than those in the control group(P<0.05). Serum VEGF and ET-1 levels in the observation group were significantly lower than those in the control group after treatment(P<0.05). Conclusion:CaD combined with compound anisodine in the treatment of NPDR can effectively improve the vision,alleviate fundus lesions,and reduce VEGF and ET-1 levels.

参考文献/References:

[1] 中华医学会糖尿病学分会.中国2型糖尿病防治指南(2017年版)[J].中华糖尿病杂志,2018,10(1):4-67.
[2] 中华医学会眼科学会眼底病学组.我国糖尿病视网膜病变临床诊疗指南(2014年)[J].中华眼科杂志,2014,50(11):851-865.
[3] 中国微循环学会糖尿病与微循环专业委员会. 糖尿病微循环障碍临床用药专家共识[J]. 中国医学前沿杂志:电子版,2017,9(2):34-41.
[4] 韩 嵩.非增殖期糖尿病性视网膜病变采用复方樟柳碱治疗的临床价值评估[J]. 中国医药指南,2018,16(16):121-122.
[5] 王真珍.芪明颗粒联合羟苯磺酸钙治疗非增殖性糖尿病性视网膜病变[J].国际眼科杂志,2017,17(4):702-705.
[6] 薛晓辉,马庆祥.血清VEGF与SE-选择素在糖尿病视网膜病变患者中的表达及意义[J].陕西医学杂志,2016,45(10):1316-1317,1320.
[7] Tarr JM,Kaul K,Chopra M,et al. Pathophysiology of diabetic retinopathy[J]. Isrn Ophthalmol,2013:343560.
[8] Gologorsky D,Thanos A,Vavvas D. Therapeutic interventions against inflammatory and angiogenic mediators in proliferative diabetic retinopathy[J]. Mediators Inflamm,2012:629452.
[9] Jariyapongskul A,Areebambud C,Suksamrarn S,et al. Alpha-mangostin attenuation of hyperglycemia-induced ocular hypoperfusion and blood retinal barrier leakage in the early stage of type 2 diabetes rats[J]. Biomed Res Int,2015:785826.
[10] Klaassen I,Van Noorden CJ,Schlingemann RO. Molecular basis of the inner blood-retinal barrier and its breakdown in diabetic macular edema and other pathological conditions[J]. Prog Retin Eye Res,2013,34:19-48.
[11] 胡卫华,刘志南. 羟苯磺酸钙治疗非增殖性糖尿病视网膜病变临床疗效观察[J].中国处方药,2013,11(6):38-39.
[12] Ribeiro ML,Seres AI. Effect of calcium dobesilate on progression of early diabetic retinopathy:a randomised double-blind study[J]. Graefes Arch Clin Exp Ophthalmol,2006,244(12):1591-1600.
[13] Zhang X,Liu W,Wu S,et al. Calcium dobesilate for diabetic retinopathy:a systematic review and meta-analysis[J]. Sci China Life Sci,2015,58(1):101-107.
[14] 殷 莉,张德龙,任 骞,等.复方丹参滴丸配合羟苯磺酸钙治疗糖尿病视网膜病效果观察[J].现代中西医结合杂志,2013,22(22):2449-2450.
[15] Zhou Y,Yuan J,Qi C,et al. Calcium dobesilate may alleviate diabetes induced endothelial dysfunction and inflammation[J]. Mol Med Rep,2017,16(6):8635-8642.
[16] 郝改梅,韩 静,徐 涛,等. 羟苯磺酸钙改善糖尿病大鼠视网膜病变及其机制研究[J]. 现代药物与临床,2015,30(5):492-496.
[17] Idris-Khodja N,Ouerd S,Mian MOR,et al. Endothelin-1 overexpression exaggerates diabetes-induced endothelial dysfunction by altering oxidative stress[J]. Am J Hypertens,2016,29(11):1245-1251.
[18] 刘 瑄,李 霞. 真武汤加减治疗2型糖尿病非增殖期视网膜病变的临床观察[J].中药材,2016,39(2):431-433.
[19] Javadzadeh A,Ghorbanihaghjo A,Adl FH,et al. Calcium dobesilate reduces endothelin-1 and high-sensitivity C-reactive protein serum levels in patients with diabetic retinopathy[J]. Mol Vis,2013,19:62-68.
[20] Hernandez C,Burgos R,Canton A,et al. Vitreous levels of vascular cell adhesion molecule and vascular endothelial growth factor in patients with proliferative diabetic retinopathy:a case-control study[J]. Diabetes Care,2001,24(3):516-521.
[21] Hernandez C,Lecube A,Segura RM,et al. Nitric oxide and vascular endothelial growth factor concentrations are increased but not related in vitreous fluid of patients with proliferative diabetic retinopathy[J]. Diabet Med,2002,19(8):655-660.
[22] Simo R,Lecube A,Segura RM,et al. Free insulin growth factor-Iand vascular endothelial growth factor in the vitreous fluid of patients with proliferative diabetic retinopathy[J]. Am J Ophthalmol,2002,134(3):376-382.
[23] 王雪燕.复方樟柳碱注射液对眼底病患者血流动力学的影响研究[J]. 中国实验诊断学,2014,18(6):958-960.
[24] 颜志勇. 复方樟柳碱治疗继发性缺血性眼底病的临床观察[J]. 吉林医学,2012,33(34):7482-7483.
[25] 赵 帅,尹 妮. 复方樟柳碱治疗眼底病患者的临床疗效及其对视力的影响[J].医学综述,2017,23(2):375-378.

备注/Memo

备注/Memo:
*陕西省自然科学基础研究面上项目(2018JM7040)
更新日期/Last Update: 2020-04-13